NCT01298687

Divided Dose of TRAVATAN®

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

• Open-angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost Ophthalmic Solution, 0.00013%	Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
DRUG	Travoprost Ophthalmic Solution, 0.00033%	Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
DRUG	Travoprost Ophthalmic Solution, 0.001%	Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
DRUG	Travoprost Ophthalmic Solution, 0.00267%	Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
DRUG	Travoprost Ophthalmic Solution, 0.004%
DRUG	Travoprost Vehicle	Inactive ingredients used as an active comparator

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2011-02-18
• Last updated: 2017-05-05